论文部分内容阅读
目的观察奥施康定用于慢性癌性疼痛治疗的安全性及不良反应发生率。方法内脏痛,骨转移痛,侵犯和压迫神经痛,皮肤黏膜痛等慢性癌性疼痛50例,应用奥施康定片剂治疗,记录治疗期间便秘、恶心呕吐、嗜睡、头痛、呼吸抑制等不良反应出现的情况。结果在治疗过程中,便秘的发生率为26%,其次为恶心呕吐8%,其他均低于5%,且不良反应随用药时间的延长有减少的趋势。结论12h服用1次的奥施康定在与临床情况相似条件下进行的历时12周的开放研究中,疼痛治疗的耐受性一直令人满意,随着时间的推移,阿片类不良反应发生减少,可以安全有效地应用于慢性癌性疼痛病人的治疗。
Objective To observe the safety and adverse reactions of oxocline in the treatment of chronic cancer pain. Methods Fifty patients with chronic cancer pain such as visceral pain, bone metastasis pain, invasion and oppression neuralgia and mucocutaneous pain were treated with OxyContin tablets. The adverse reactions such as constipation, nausea and vomiting, lethargy, headache and respiratory depression were recorded during the treatment What happened? Results During the treatment, the incidence of constipation was 26%, followed by 8% of nausea and vomiting, the others were less than 5%, and the adverse reactions tended to decrease with the prolongation of treatment time. Conclusions Oxycodin taken once 12 h had a satisfactory tolerability of pain management in a 12-week open-label study under similar conditions to clinical conditions, with a decrease in the incidence of opioid adverse reactions over time, It can safely and effectively be used in the treatment of patients with chronic cancer pain.